HLS Therapeutics Inc. announces that Dr. Kyle Dempsey has been appointed to the board of directors of the Company (the "Board") as an independent director. Dr. Dempsey is a partner at MVM Partners ("MVM"), a healthcare focused private equity fund based in Boston, Massachusetts and London, UK. While at MVM, Dr. Dempsey has led investments and served as a board director in private and public companies, including NASDAQ-listed specialty pharmaceutical company Optinose Inc. and GT Medical Technologies Inc.; he is also an observer on the board of MDxHealth SA and was previously a board observer of Biotheranostics Inc. (acquired by Hologic).

Prior to MVM, he was a consultant at Bain & Company where he worked on cases across various healthcare sub-sectors. Dr. Dempsey has M.D. and M.B.A. degrees from Harvard University and a B.A. in biochemistry from Bowdoin College.